NMPA Approves IND Application for CT103A, A Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma codeveloped by IASO BIO and Innovent Bio

Clinical Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by IASO BIO and Innovent Presented at the 2019 ASCO and EHA Annual Meetings